Fact checked byErik Swain

Read more

October 17, 2023
3 min read
Save

CMHC spotlights impact of digital health, social determinants on cardiometabolic care

Fact checked byErik Swain
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • The Cardiometabolic Health Congress takes place Oct. 18-21 in Boston.
  • This year’s congress includes a special track focused on digital health and technology.

The 2023 Cardiometabolic Health Congress will return in-person to Boston with the latest updates spanning all aspects of cardiometabolic health, including CVD, diabetes, kidney disease, lipid and lifestyle management and obesity.

This year’s 18th Annual Cardiometabolic Health Congress: Social Determinants and Digital Advances in Cardiorenal Metabolic Health, will take place from Oct. 18 to 21 at the Boston Park Plaza, welcoming a provider audience, expert faculty and industry pillars for 4 days of didactic lectures, interactive sessions, expert roundtables, audience Q&As and more educational opportunities. In addition to an agenda full of management pearls for complex cardiometabolic conditions, this year’s congress will introduce a special track focused on digital health interventions and their practice applications, as well as several focused sessions on the importance of assessing social determinants of health, according to Anne L. Peters, MD, professor of clinical medicine at Keck School of Medicine of the University of Southern California and co-chair of the CMHC conference.

microphone at meeting
The Cardiometabolic Health Congress takes place Oct. 18-21 in Boston.
Image: Adobe Stock

The first day of the meeting will serve as a pre-conference dedicated to the role of digital health and technology in cardiometabolic risk reduction. The day’s agenda includes sessions on health and care apps for lifestyle and obesity, continuous glucose monitoring for lifestyle management, using digital health for long-term weight management and panel discussions on digital health in type 2 diabetes and CVD and CVD risk reduction. The day will conclude with a “fireside chat” with insights from industry on digital interventions.

Anne L. Peters

“I like that this meeting is talking about digital health, but not just for diabetes,” Peters told Healio. “This is a rapidly evolving area with more and more devices. There are many digital tools, and the question is, how can these tools work to best sustain behavior changes? You can monitor something for 1 week, but what happens over 1 year and what does it mean for health outcomes? How do we interpret these tools and what do we tell our patients? This particular day, the first day, will be fascinating.”

Other highlights of this year’s CMHC include:

  • A. Enrique Caballero, MD, will present this year’s keynote address on screening for social determinants of cardiometabolic health and practice implications on Thursday at 10:15 a.m.
  • Debate: Is it time to compare high-intensity pharmacotherapy with surgery for the management of obesity? Donna H. Ryan, MD, and Christopher D. Still, DO, will debate and discuss the topic on Thursday at 1:45 p.m.
  • CMHC’s annual spotlight on the latest FDA updates and late-breaking trials in cardiometabolic medicine will continue at 10:15 a.m. on Thursday, featuring Deepak L. Bhatt, MD; Robert H. Eckel, MD, Keith C. Ferdinand, MD; and Peters
  • Alanna A. Morris, MD, MSc, FHFSA, FACC, FAHA, will focus on the continuum of HF on Saturday at 11:10 a.m.

The agenda also includes several CME symposia and challenging cases and panel discussions.

“The biggest strength of this is the interaction between the faculty and attendees,” Peters told Healio. “That is where people can really learn a lot.

“There is a lot of depth to the speakers and their ability to talk about what is new — and there is a lot that is new,” Peters said. “This goes beyond the old paradigms, looking at things like colchicine as an adjunct to statin therapies, or how to deal with statin intolerance or hypertriglyceridemia. It takes what we know and enhances it, both from novel ways of looking at it and looking at not only what works, but what does not.”

Healio is an official media partner of CMHC. The Healio team will provide coverage from the meeting, including reports on the sessions above and more. Follow along at this link and on X (Twitter) at @CardiologyToday.

Reference: